| 2.38 0.07 (3.03%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.96 | 1-year : | 3.22 |
| Resists | First : | 2.53 | Second : | 2.75 |
| Pivot price | 2.3 |
|||
| Supports | First : | 2.18 | Second : | 1.81 |
| MAs | MA(5) : | 2.32 |
MA(20) : | 2.38  |
| MA(100) : | 2.87 |
MA(250) : | 3.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 33.8 |
D(3) : | 25.4 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 7.76 | Low : | 2.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLRX ] has closed Bollinger Bands are 30.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.41 | 2.41 - 2.42 |
| Low: | 2.24 - 2.25 | 2.25 - 2.26 |
| Close: | 2.29 - 2.31 | 2.31 - 2.32 |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Fri, 10 Apr 2026
BioLineRx (BLRX) director Yan Shaoyu submits Form 3 with no trades - Stock Titan
Tue, 31 Mar 2026
BioLineRx (BLRX) director details extensive stock option grants - Stock Titan
Tue, 31 Mar 2026
BioLineRx (BLRX) director Dar Rami reports multiple employee stock option grants - Stock Titan
Tue, 31 Mar 2026
BioLineRx (NASDAQ: BLRX) director details extensive stock option grants - Stock Titan
Mon, 30 Mar 2026
BioLineRx (BLRX) director discloses 2,055,000 option-linked shares - Stock Titan
Mon, 30 Mar 2026
[Form 3] BioLineRx Ltd. Initial Statement of Beneficial Ownership - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.5e+009 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 167 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.006e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -99.6 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 745.3 % |
| Return on Equity (ttm) | -16.2 % |
| Qtrly Rev. Growth | 1.18e+006 % |
| Gross Profit (p.s.) | -213.7 |
| Sales Per Share | -23.94 |
| EBITDA (p.s.) | 2.06522e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 112.69 |
| Dividend | 0 |
| Forward Dividend | 167580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|